Search results for: Milena Weber

Items from 1 to 18 out of 18 results

article

Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy

Musa Khaitov, Igor Shilovskiy, Rudolf Valenta, Milena Weber, more

Allergy > 79 > 4 > 1001 - 1017

Background IgE cross‐sensitization to major birch pollen allergen Bet v 1 and pathogenesis‐related (PR10) plant food allergens is responsible for the pollen‐food allergy syndrome. Methods We designed a recombinant protein, AB‐PreS, consisting of non‐allergenic peptides derived from the IgE‐binding sites of Bet v 1 and the cross‐reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface...

article

Natural human Bet v 1‐specific IgG antibodies recognize non‐conformational epitopes whereas IgE reacts with conformational epitopes

Georgii Brazhnikov, Evgenii Smolnikov, Alla Litovkina, Tianchi Jiang, more

Allergy > 78 > 12 > 3136 - 3153

Background The nature of epitopes on Bet v 1 recognized by natural IgG antibodies of birch pollen allergic patients and birch pollen‐exposed but non‐sensitized subjects has not been studied in detail. Objective To investigate IgE and IgG recognition of Bet v 1 and to study the effects of natural Bet v 1‐specific IgG antibodies on IgE recognition of Bet v 1 and Bet v 1‐induced basophil activation...

article

Combined assessment of S‐ and N‐specific IL‐2 and IL‐13 secretion and CD69 neo‐expression for discrimination of post–infection and post‐vaccination cellular SARS‐CoV‐2‐specific immune response

Bernhard Kratzer, Larissa C. Schlax, Pia Gattinger, Petra Waidhofer‐Söllner, more

Allergy > 77 > 11 > 3408 - 3425

Background Antibody‐based tests are available for measuring SARS‐CoV‐2‐specific immune responses but fast T‐cell assays remain scarce. Robust T cell‐based tests are needed to differentiate specific cellular immune responses after infection from those after vaccination. Methods One hundred seventeen individuals (COVID‐19 convalescent patients: n = 40; SARS‐CoV‐2 vaccinees: n = 41; healthy controls:...

article

Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes

Pia Gattinger, Katarzyna Niespodziana, Karin Stiasny, Sabina Sahanic, more

Allergy > 77 > 1 > 230 - 242

Background The determinants of successful humoral immune response to the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are of critical importance for the design of effective vaccines and the evaluation of the degree of protective immunity conferred by exposure to the virus. As novel variants emerge, understanding their likelihood of suppression by population antibody repertoires has...

article

Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations

Bernhard Kratzer, Doris Trapin, Paul Ettel, Ulrike Körmöczi, more

Allergy > 76 > 3 > 751 - 765

Background SARS‐CoV‐2 has triggered a pandemic that is now claiming many lives. Several studies have investigated cellular immune responses in COVID‐19‐infected patients during disease but little is known regarding a possible protracted impact of COVID‐19 on the adaptive and innate immune system in COVID‐19 convalescent patients. Methods We used multiparametric flow cytometry to analyze whole peripheral...

article

Allergen immunotherapy with the hypoallergenic B‐cell epitope‐based vaccine BM32 modifies IL‐10‐ and IL‐5‐secreting T cells

Michèle Myriam Rauber, Christian Möbs, Raffaela Campana, Rainer Henning, more

Allergy > 75 > 2 > 450 - 453

article

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32

Verena Niederberger, Angela Neubauer, Philippe Gevaert, Mihaela Zidarn, more

Journal of Allergy and Clinical Immunology > 2018 > 142 > 2 > 497-509.e9

BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein.We sought to study the safety and clinical efficacy of immunotherapy (allergen immunotherapy) with BM32 in patients with grass pollen–induced rhinitis and controlled asthma.A double-blind,...

article

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Milena Weber, Katarzyna Niespodziana, Birgit Linhart, Angela Neubauer, more

Journal of Allergy and Clinical Immunology > 2017 > 140 > 5 > 1433-1436.e6

article

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy

Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, more

EBioMedicine > 2017 > 17 > Complete > 119-133

Prevention of IgE-binding to cellular IgE-receptors by anti-IgE (Omalizumab) is clinically effective in allergic asthma, but limited by IgE threshold-levels. To overcome this limitation, we developed a single-use IgE immunoadsorber column (IgEnio). IgEnio is based on a recombinant, IgE-specific antibody fragment and can be used for the specific extracorporeal desorption of IgE.To study safety and...

article

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy

Petra Zieglmayer, Margarete Focke-Tejkl, René Schmutz, Patrick Lemell, more

EBioMedicine > 2016 > 11 > Complete > 43-57

We have developed a recombinant B cell epitope-based vaccine (BM32) for allergen-specific immunotherapy (AIT) of grass pollen allergy. The vaccine contains recombinant fusion proteins consisting of allergen-derived peptides and the hepatitis B surface protein domain preS as immunological carrier.We conducted a randomized, double-blind, placebo-controlled AIT study to determine safety, clinical efficacy...

article

Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection

Carolin Cornelius, Katrin Schöneweis, Fanny Georgi, Milena Weber, more

EBioMedicine > 2016 > 11 > Complete > 58-67

We have constructed and clinically evaluated a hypoallergenic vaccine for grass pollen allergy, BM32, which is based on fusion proteins consisting of peptides from the IgE binding sites of the major grass pollen allergens fused to preS (preS1+preS2), a domain of the hepatitis B virus (HBV) large envelope protein which mediates the viral attachment and entry. Aim of this study was the characterization...

article

IgE epitope proximity determines immune complex shape and effector cell activation capacity

Anna Gieras, Birgit Linhart, Kenneth H. Roux, Moumita Dutta, more

Journal of Allergy and Clinical Immunology > 2016 > 137 > 5 > 1557-1565

IgE-allergen complexes induce mast cell and basophil activation and thus immediate allergic inflammation. They are also important for IgE-facilitated allergen presentation to T cells by antigen-presenting cells.To investigate whether the proximity of IgE binding sites on an allergen affects immune complex shape and subsequent effector cell activation in vitro and in vivo.We constructed artificial...

article

Usefulness of recombinant γ-gliadin 1 for identifying patients with celiac disease and monitoring adherence to a gluten-free diet

Bharani Srinivasan, Margarete Focke-Tejkl, Milena Weber, Sandra Pahr, more

Journal of Allergy and Clinical Immunology > 2015 > 136 > 6 > 1607-1618.e3

Celiac disease (CD) is an inflammatory disease of the small intestine caused by an immunologic hypersensitivity reaction to dietary wheat gluten.We sought to clone, express, and perform IgA epitope mapping of a CD-specific wheat antigen and to study its usefulness for identifying patients with CD and monitoring adherence to a gluten-free diet.A synthetic gene coding for γ-gliadin 1 (GG1) was expressed...

article

Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen–allergic patients

Verena Niederberger, Katharina Marth, Julia Eckl-Dorna, Margarete Focke-Tejkl, more

The Journal of Allergy and Clinical Immunology > 2015 > 136 > 4 > 1101-1103.e8

article

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy

Margarete Focke-Tejkl, Milena Weber, Katarzyna Niespodziana, Angela Neubauer, more

The Journal of Allergy and Clinical Immunology > 2015 > 135 > 5 > 1207-1217.e11

Grass pollen is one of the most important sources of respiratory allergies worldwide.This study describes the development of a grass pollen allergy vaccine based on recombinant hypoallergenic derivatives of the major timothy grass pollen allergens Phl p 1, Phl p 2, Phl p 5, and Phl p 6 by using a peptide-carrier approach.Fusion proteins consisting of nonallergenic peptides from the 4 major timothy...

article

A general strategy for the generation of hypoallergenic molecules for the immunotherapy of fish allergy

Ines Swoboda, Nadja Balic, Christoph Klug, Margit Focke, more

The Journal of Allergy and Clinical Immunology > 2013 > 132 > 4 > 979-981.e1

article

Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy

Tetiana Garmatiuk, Ines Swoboda, Anna Twardosz-Kropfmüller, Fabio Dall’Antonia, more

Immunobiology > 2013 > 218 > 9 > 1155-1165

The major turnip (Brassica rapa) pollen allergen, belongs to a family of calcium-binding proteins (i.e., two EF-hand proteins), which occur as highly cross-reactive allergens in pollen of weeds, grasses and trees. In this study, the IgE binding capacity and allergenic activity of three recombinant allergen variants containing mutations in their calcium-binding sites were analyzed in sensitized patients...

article

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy

Teresa E. Twaroch, Margit Focke, Vera Civaj, Milena Weber, more

The Journal of Allergy and Clinical Immunology > 2011 > 128 > 1 > 178-184.e7

Trees of the family Oleaceae (olive and ash) are important allergen sources in Mediterranean countries, Northern and Central Europe, and North America. The major olive pollen allergen Ole e 1 represents the majority of allergenic epitopes in olive pollen and cross-reacts with Fra e 1, the major ash pollen allergen.We sought to develop a safe vaccine for the treatment of Oleaceae pollen allergy.We...

Filter options

Publication date

Last year (2)
Last 3 years (4)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Milena Weber

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options